A 6-week randomized, double-blind, placebo-controlled, crossover study to assess the effect of fluticasone 250microg/salmeterol 50microg combination (FSC 250/50) on exertional dyspnea in patients with symptomatic mild COPD [chronic obstructive pulmonary disease].

Trial Profile

A 6-week randomized, double-blind, placebo-controlled, crossover study to assess the effect of fluticasone 250microg/salmeterol 50microg combination (FSC 250/50) on exertional dyspnea in patients with symptomatic mild COPD [chronic obstructive pulmonary disease].

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2013

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary)
  • Indications Chronic obstructive pulmonary disease; Dyspnoea
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Apr 2010 Actual patient number (18) added as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top